Vaxcyte Inc
Vaxcyte Inc is a clinical-stage biotechnology company focused on developing next-generation vaccines and immune therapies.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Vaxcyte's stock with a target price of $103.14, indicating strong potential growth.
Financial Health
Vaxcyte Inc is performing well with strong cash flow and a healthy book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring PCVX
The Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Late-stage pneumococcal play
Vaxcyte’s pneumococcal candidate aims to expand serotype coverage, which could address unmet need — though success depends on clinical and regulatory outcomes.
Platform-driven vaccine pipeline
A proprietary platform supports multiple candidates, offering leverage if one succeeds; early-stage programmes add upside but also add development risk.
Commercial and competitive dynamics
The global vaccine market offers scale if approved, but competition from established vaccine makers and manufacturing challenges can affect commercial prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
